The Public Health Insurance Coverage of Novel Targeted Anticancer Medicines in China-In Favor of Whom? A Retrospective Analysis of the Insurance Claim Data.

With an increasing number of novel medicines covered by the public health insurance program, the total number of patients under medications of interest will be an increasing trend overall, while the medications with different medicines of interest may vary due to the competition of interchangeable generics or bio-similars or the competition of alternative therapeutics with the same indication ( Diao et al., 2019 ).

also in 63,971 other papers